Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

, PFE

Pfizer

$32.50

-0.16 (-0.49%)

08:55
10/18/16
10/18
08:55
10/18/16
08:55

J&J 'confident' can see pharmaceutical growth through 2019 despite biosimilars

Johnson & Johnson (JNJ) said in slides for its Q3 earnings call that the company remains confident it can deliver "strong growth" in pharmaceuticals through 2019 in the "face of biosimilar competition and market dynamics." From 2015-2019, J&J sees 40 potential line extensions, ten of which it identifies as having $500M+ potential. In that timeframe, J&J sees ten potential $1B+ new molecular entities, five of which it identifies as "significant near-term opportunities with higher certainty and higher value than originally anticipated." Additionally, the company said that its U.S. Remicade biosimilar readiness plan "is in place." Last night, Pfizer (PFE) announced that the company will begin shipment of Inflectra for injection, a biosimilar of Remicade, to wholesalers in the United States in late November 2016.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

PFE

Pfizer

$32.50

-0.16 (-0.49%)

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 27

    Oct

  • 01

    Nov

  • 06

    Nov

JNJ Johnson & Johnson
$118.49

0.93 (0.79%)

09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
PFE Pfizer
$32.50

-0.16 (-0.49%)

10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/16
UBSW
10/18/16
NO CHANGE
Target $38
UBSW
Buy
Pfizer risk/reward favorable at current levels, says UBS
UBS analyst Marc Goodman likes the current risk/reward for Pfizer shares. He believes the shares will move higher as top-line growth improves, its pipeline appreciation gets better, and management continues to be aggressive with M&A. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.

TODAY'S FREE FLY STORIES

PPC

Pilgrim's Pride

$28.91

-0.63 (-2.13%)

09:07
09/20/17
09/20
09:07
09/20/17
09:07
Conference/Events
Pilgrim's Pride holds an investor day »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MSFT

Microsoft

$75.44

0.28 (0.37%)

, GD

General Dynamics

$203.12

0.94 (0.46%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Microsoft General Dynamics and Dell EMC awarded $1B Air Force contract »

General Dynamics (GD),…

MSFT

Microsoft

$75.44

0.28 (0.37%)

GD

General Dynamics

$203.12

0.94 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

JAGX

Jaguar Health

$0.38

-0.02 (-5.00%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Jaguar Health's Canalevia qualifies as 'minor use' for EID in dogs »

Jaguar Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOS

MYOS

$1.59

0.28 (21.37%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
MYOS names Joseph Mannello as CEO, effective August 24 »

MYOS RENS Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
09/20/17
09/20
09:05
09/20/17
09:05
General news
U.S. equities are stuck in the Fed's headlights »

U.S. equities are stuck…

SGMS

Scientific Games

$43.10

1.05 (2.50%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Scientific Games to acquire NYX Gaming Group for C$2.40 per share »

Scientific Games and NYX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

PG

Procter & Gamble

$94.17

1.02 (1.10%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Trian: Initiatives will make P&G 'best-in-class company once again' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$52.09

-4.48 (-7.92%)

09:03
09/20/17
09/20
09:03
09/20/17
09:03
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Breaking Hot Stocks news story on Rent-A-Center »

Rent-A-Center says August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$13.63

0.18 (1.34%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
American Eagle to expand to India through licensed stores »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

, GOOG

Alphabet

$921.81

6.81 (0.74%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Periodicals
Google said to acquire certain HTC assets, VentureBeat's Bass reports »

VentureBeat reporter Evan…

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Rent-A-Center reports core U.S. SSS down 5.3% in August »

Rent-A-Center, announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

09:01
09/20/17
09/20
09:01
09/20/17
09:01
Conference/Events
Meet Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EDVMF

Endeavour Mining

$18.42

-0.0721 (-0.39%)

09:00
09/20/17
09/20
09:00
09/20/17
09:00
Conference/Events
Endeavour Mining holds a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Hot Stocks
General Mills says cereal sales improved in August »

Expects to improve yogurt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CIEN

Ciena

$22.08

-0.26 (-1.16%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
Ciena analyst commentary  »

Ciena FY18 growth more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

FDX

FedEx

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

BPMC

Blueprint Medicines

$63.86

0.98 (1.56%)

08:56
09/20/17
09/20
08:56
09/20/17
08:56
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.86

0.16 (0.65%)

, S

Sprint

$8.20

0.52 (6.77%)

08:55
09/20/17
09/20
08:55
09/20/17
08:55
Options
Notable open interest changes for September 20th »

Tuesday's total…

BAC

Bank of America

$24.86

0.16 (0.65%)

S

Sprint

$8.20

0.52 (6.77%)

T

AT&T

$38.21

0.79 (2.11%)

BABA

Alibaba

$180.07

0.09 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

  • 16

    May

RARE

Ultragenyx

$51.90

-1.09 (-2.06%)

08:54
09/20/17
09/20
08:54
09/20/17
08:54
Conference/Events
Ultragenyx has a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

WBC

Wabco

$146.87

3.9 (2.73%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Conference/Events
Wabco holds a conference call »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.